• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    NEW!!! Clinical Investigator Toolkit

    We are pleased to announce the development of the Clinical Investigator Toolkit

    Breast cancer specialist Paula Ryan and basic scientist Leif Ellisen, of MGH, are co-investigators on a phase II trial of cisplatin for triple negative breast cancer.
    Divide-and-conquer strategy drives breast cancer breakthroughs

    Pulling a page from ancient Rome’s military handbook, investigators in the DF/HCC Breast Cancer Program are deploying a divide-and-conquer strategy in the battle against breast cancer

    HER2+ breast cancer cells transfected with siRNAs are grown in the presence or absence of Herceptin for four days. Then cell viability and number are measured.
    siRNA knockdowns turn up intriguing HER2 targets

    At best, only 20 to 30 percent of women with HER2-positive breast cancer respond to trastuzumab

    Fusion of renal carcinoma and DCs stained for Cytokeratin (red) and CD86 (blue) 100x.
    Fusion vaccine plus surgery may prove potent combination in renal cell cancer

    Renal cell cancer (RCC) is a life-threatening malignancy considered incurable in the metastatic setting

    Breakefield awarded $5.8 million to study tumors

    DF/HCC member Xandra Breakefield, PhD (MGH) will receive approximately $5.8 million in total costs over five years to study the genetic and cellular factors contributing to the formation and progression of benign tumors in the nervous system

    Harvard receives transforming NIH award

    Harvard Medical School has been awarded the Clinical and Translational Science Award (CTSA) from the National Institutes of Health

    DePinho awarded $10.8 million to study malignant gliomas

    DF/HCC member Ronald DePinho, MD (DFCI) has successfully renewed funding from the NCI to better understand the pathogenesis of glioblastoma multiforme (GBM)

Displaying results 134 to 140 out of 206